Healthcare Services

Treatment-Resistant Depression Market Overview 2026–2030 with Insights

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Treatment-Resistant Depression Market Grow Between 2026 And 2030?

The treatment-resistant depression market has shown significant expansion in recent years. It is projected to increase from $1.87 billion in 2025 to $2 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.9%. This historical growth can be attributed to factors such as the rising prevalence of major depressive disorder, the limited efficacy of conventional antidepressants, an increased diagnosis of refractory depression cases, the expansion of psychiatric specialty clinics, and the growing acceptance of advanced mental health therapies.

The market size for treatment-resistant depression is predicted to undergo significant expansion over the next few years, with projections indicating it will reach $2.59 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.7%. This anticipated growth is largely attributed to several factors including increasing investments in precision psychiatry, the growing approval of ketamine and esketamine therapies, the expansion of biomarker-driven treatment selection, a rising demand for long-term depression management solutions, and the increased use of digital therapeutic support tools. Furthermore, major trends anticipated in the forecast period encompass the increasing adoption of novel rapid-acting antidepressants, rising utilization of neuromodulation therapies, a growing focus on personalized psychiatry approaches, the expansion of psychedelic-based treatment research, and enhanced integration of digital mental health tools.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23546&type=smp

What Key Drivers Are Fueling The Growth Of The Treatment-Resistant Depression Market?

The widespread occurrence of mental disorders is projected to boost the expansion of the treatment-resistant depression market. Mental disorders are diverse conditions affecting cognitive, emotional, and behavioral functioning, often causing substantial distress and daily impairment. This elevated prevalence is influenced by factors such as genetic predisposition, where inherited genetic variations can impact brain chemistry and heighten susceptibility to conditions like depression, anxiety, and schizophrenia. Treatment-resistant depression (TRD) supports individuals with mental disorders by promoting advanced, personalized treatments when standard therapies fail, ultimately improving their recovery chances and quality of life. For example, in November 2023, the American Psychological Association (APA), a US-based scientific and professional organization, reported that among adults, those aged 18 to 34 had the highest rate of mental illnesses at 50% in 2023, while adults aged 35 to 44 saw the largest increase in diagnoses, with 45% reporting a mental illness. Thus, the high prevalence of mental disorders is a key driver for the growth of the treatment-resistant depression market.

Which Segment Classifications Are Used In The Treatment-Resistant Depression Market Segment Analysis?

The treatment-resistant depression market covered in this report is segmented –

1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIs), Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Psychedelics

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram

2) By Monoamine Oxidase Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline

3) By Tricyclic Antidepressants (TCAs): Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Doxepin

4) By Psychedelics: Ketamine, Esketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA)

What Trends Are Influencing The Treatment-Resistant Depression Market?

Leading companies in the treatment-resistant depression sector are prioritizing the creation of novel treatments, including monotherapy, to fulfill unmet patient requirements, boost effectiveness, and minimize adverse reactions. Monotherapy involves using a singular treatment or drug for a condition, rather than administering multiple therapies concurrently. This approach aids in managing treatment-resistant depression by providing a singular, concentrated therapy that could prove more beneficial for individuals who have not responded to various preceding medications. As an illustration, Johnson & Johnson Services Inc., a pharmaceutical, biotechnology, and medical technology firm based in the U.S., declared in January 2025 that the U.S. Food and Drug Administration (FDA), a U.S. government regulatory agency, had granted approval for SPRAVATO (esketamine) nasal spray, a rapid-onset therapy for adults suffering from treatment-resistant depression (TRD). SPRAVATO is administered in conjunction with an oral antidepressant when individuals have shown an insufficient response to at least two other antidepressant regimens. The swift impact of this medication overcomes the shortcomings of conventional antidepressants, which typically require several weeks to demonstrate efficacy. Derived from ketamine, esketamine functions by targeting NMDA receptors in the brain, with the potential to elevate mood within a few hours. This approval represented a substantial stride forward in the domain of mental health care.

Which Firms Are Contributing To The Treatment-Resistant Depression Market Ecosystem?

Major companies operating in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience

Get The Full Treatment-Resistant Depression Market Report:

https://www.thebusinessresearchcompany.com/report/treatment-resistant-depression-global-market-report

Which Region Is The Largest In The Treatment-Resistant Depression Market?

North America was the largest region in the treatment-resistant depression market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the treatment-resistant depression market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Treatment-Resistant Depression Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/treatment-resistant-depression-global-market-report

Browse Through More Reports Similar to the Global Treatment-Resistant Depression Market 2026, By The Business Research Company

Major Depressive Disorder Market Report 2026

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Music Therapy Market Report

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Behavioral Therapy Market Report

https://www.thebusinessresearchcompany.com/report/behavioral-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795